MYIA
BCRX icon

Mount Yale Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mount Yale Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Sell
12,556
-442
-3% -$4K ﹤0.01% 1167
2026
Q1 		$124K Buy
12,998
+875
+7% +$6.79K ﹤0.01% 1076
2025
Q4 		$94.6K Buy
12,123
+1,395
+13% +$10.1K ﹤0.01% 709
2025
Q3 		$81.4K Buy
+10,728
New +$89.3K 0.01% 661

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Mount Yale Investment Advisors's BCRX Position: Q2 2026 in Review

Mount Yale Investment Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 3.4% in Q2 2026, selling an estimated $4K and leaving 12,556 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Mount Yale Investment Advisors first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Mount Yale Investment Advisors held 12,556 shares of BioCryst Pharmaceuticals worth $126K as of Q2 2026.
  • Mount Yale Investment Advisors sold 442 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $4K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #1167 holding.
  • Mount Yale Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.